National and State Estimates of Lost Earnings From Cancer Deaths in the United States.

Importance Information on the economic burden of cancer mortality can serve as a tool in setting policies and prioritizing resources for cancer prevention and control. However, contemporary data are lacking for the United States nationally and by state. Objective To estimate lost earnings due to death from cancer overall and for the major cancers in the United States nationally and by state. Design, Setting, and Participants Person-years of life lost (PYLL) were calculated using numbers of cancer deaths and life expectancy data in individuals aged 16 to 84 years who died from cancer in the United States in 2015. The annual median earnings in the United States were used to assign a monetary value for each PYLL by age and sex. Cancer mortality and life expectancy data were obtained from the National Center for Health Statistics and annual median earnings from the US Census Bureau's 2016 Current Population Survey's March Annual Social and Economic Supplement. Data analysis was performed from October 22, 2018, to February 25, 2019. Main Outcomes and Measures Lost earnings due to cancer death, represented as estimated future wages in the absence of premature death. Results A total of 8 739 939 person-years of life were lost to cancer death in persons aged 16 to 84 years in the United States in 2015, translating to lost earnings of $94.4 billion (95% CI, $91.7 billion-$97.3 billion). For individual cancer sites, lost earnings were highest for lung cancer ($21.3 billion), followed by colorectal ($9.4 billion), female breast ($6.2 billion), and pancreatic ($6.1 billion) cancer. Age-standardized lost earning rates per 100 000 were lowest in the West and highest in the South, ranging from $19.6 million (95% CI, $19.1 million-$20.2 million) in Utah to $35.3 million ($34.4 million-$36.3 million) in Kentucky. Approximately 2.4 million PYLL and $27.7 billion (95% CI, $26.9 billion-$28.5 billion) in lost earnings (29.3% of total that occurred in 2015) would have been avoided in 2015 if all states had the same age-specific PYLL or lost earning rates as Utah. Conclusions and Relevance Our findings indicate large state variation in the economic burden of cancer and suggest the potential for substantial financial benefit through delivery of effective cancer prevention, screening, and treatment to minimize premature cancer mortality in all states.

[1]  M. Rothberg,et al.  Assessing Years of Life Lost Versus Number of Deaths in the United States, 1995-2015 , 2017, American journal of public health.

[2]  Angela Mariotto,et al.  Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[3]  E. Feuer,et al.  Productivity costs of cancer mortality in the United States: 2000-2020. , 2008, Journal of the National Cancer Institute.

[4]  E. Feuer,et al.  Estimates and projections of value of life lost from cancer deaths in the United States. , 2008, Journal of the National Cancer Institute.

[5]  S. Fedewa,et al.  Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening , 2018, CA: a cancer journal for clinicians.

[6]  A. Jemal,et al.  Potentially preventable premature lung cancer deaths in the USA if overall population rates were reduced to those of educated whites in lower-risk states , 2015, Cancer Causes & Control.

[7]  T. Richards,et al.  Use of Colorectal Cancer Screening Tests by State , 2018, Preventing chronic disease.

[8]  D. Ekwueme,et al.  Health and economic impact of breast cancer mortality in young women, 1970-2008. , 2014, American journal of preventive medicine.

[9]  The State of Cancer Care in America, 2017: A Report by the American Society of Clinical Oncology. , 2017, Journal of oncology practice.

[10]  Anne C. Haddix,et al.  Prevention effectiveness : a guide to decision analysis and economic evaluation , 1996 .

[11]  Ahmedin Jemal,et al.  Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015 , 2017, JAMA oncology.

[12]  D. Ekwueme,et al.  Economic Burden of Chronic Conditions Among Survivors of Cancer in the United States. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Sander Greenland,et al.  Interval estimation by simulation as an alternative to and extension of confidence intervals. , 2004, International journal of epidemiology.

[14]  S. J. Henley,et al.  Years of Life and Productivity Loss from Potentially Avoidable Colorectal Cancer Deaths in U.S. Counties with Lower Educational Attainment (2008–2012) , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[15]  E. Arias,et al.  United States Life Tables, 2015. , 2018, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[16]  F. Bray,et al.  Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): A population-based comparison. , 2018, Cancer epidemiology.

[17]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[18]  D. Ekwueme,et al.  Annual Patient Time Costs Associated With Medical Care Among Cancer Survivors in the United States , 2014, Medical care.

[19]  D. Ekwueme,et al.  Assessing the Burden of HPV-Associated Cancers in the United States , 2008 .

[20]  A. Jemal,et al.  Updated Review of Prevalence of Major Risk Factors and Use of Screening Tests for Cancer in the United States , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[21]  R. Jagsi,et al.  Racial disparities in guideline-concordant cancer care and mortality in the United States , 2018, Advances in radiation oncology.

[22]  Ted Gansler,et al.  An assessment of progress in cancer control , 2018, CA: a cancer journal for clinicians.

[23]  Ahmedin Jemal,et al.  Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States , 2018, CA: a cancer journal for clinicians.

[24]  M. Phipps,et al.  Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[25]  C. Klabunde,et al.  Cancer Screening Test Use — United States, 2013 , 2015, MMWR. Morbidity and mortality weekly report.

[26]  A. Jemal,et al.  Secular Trends in Mortality From Common Cancers in the United States by Educational Attainment, 1993–2001 , 2008, Journal of the National Cancer Institute.

[27]  N. Rigotti,et al.  Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. , 2015, JAMA internal medicine.

[28]  A. Jemal,et al.  Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. , 2016, Journal of the National Cancer Institute.

[29]  R. Giuntoli,et al.  Geographic access to gynecologic cancer care in the United States. , 2015, Gynecologic oncology.

[30]  C. Klabunde,et al.  Barriers to colorectal cancer screening among Medicare consumers. , 2006, American journal of preventive medicine.

[31]  A. Jemal,et al.  Association Between Geographic Access to Cancer Care, Insurance, and Receipt of Chemotherapy: Geographic Distribution of Oncologists and Travel Distance. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Richard Sullivan,et al.  Economic burden of cancer across the European Union: a population-based cost analysis. , 2013, The Lancet. Oncology.

[33]  S. Stokley,et al.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017 , 2018, MMWR. Morbidity and mortality weekly report.

[34]  M. Svensson,et al.  The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature. , 2015, Health economics.

[35]  L. Sharp,et al.  The cost of premature cancer-related mortality: a review and assessment of the evidence , 2014, Expert review of pharmacoeconomics & outcomes research.

[36]  T. Thompson,et al.  Cancer Screening Test Use — United States, 2015 , 2017, MMWR. Morbidity and mortality weekly report.

[37]  A. Jemal,et al.  Factors That Contribute to Differences in Survival of Black vs White Patients With Colorectal Cancer. , 2017, Gastroenterology.

[38]  Morgan M. Millar,et al.  Disparities in cancer survival and incidence by metropolitan versus rural residence in Utah , 2018, Cancer medicine.

[39]  A. Jemal,et al.  Cancer mortality in the United States by education level and race. , 2007, Journal of the National Cancer Institute.

[40]  A. Jemal,et al.  Variations in Receipt of Curative‐Intent Surgery for Early‐Stage Non–Small Cell Lung Cancer (NSCLC) by State , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  J. Griggs,et al.  Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute , 2017, CA: a cancer journal for clinicians.

[42]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.